CEL-SCI Company Profile (NYSEMKT:CVM)


CEL-SCI logoCEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for treatment of certain head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus and human papillomavirus co-infected patients and Ligand Epitope Antigen Presentation System (L.E.A.P.S.) technology, with over two investigational therapies, LEAPS-H1N1-DC, a product candidate under development for treatment of pandemic influenza in hospitalized patients, and CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:CVM
  • CUSIP: N/A
  • Web: N/A
  • Market Cap: $19.88 million
  • Outstanding Shares: 229,827,000
Average Prices:
  • 50 Day Moving Avg: $0.10
  • 200 Day Moving Avg: $0.12
  • 52 Week Range: $0.06 - $0.55
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.30
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $265,736.00
  • Price / Sales: 74.81
  • Book Value: ($0.01) per share
  • Price / Book: -6.18
  • EBIDTA: ($28,260,000.00)
  • Average Volume: 3.70 million shs.
  • Beta: -0.28
  • Short Ratio: 2.82

Frequently Asked Questions for CEL-SCI (NYSEMKT:CVM)

What is CEL-SCI's stock symbol?

CEL-SCI trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "CVM."

How were CEL-SCI's earnings last quarter?

CEL-SCI Co. (NYSEMKT:CVM) issued its earnings results on Wednesday, May, 10th. The company reported ($0.05) earnings per share (EPS) for the quarter. The company had revenue of $0.02 million for the quarter. View CEL-SCI's Earnings History.

Who are some of CEL-SCI's key competitors?

How do I buy CEL-SCI stock?

Shares of CEL-SCI can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of CEL-SCI stock cost?

One share of CEL-SCI stock can currently be purchased for approximately $0.09.

Analyst Ratings

Consensus Ratings for CEL-SCI (NYSEMKT:CVM) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for CEL-SCI (NYSEMKT:CVM)
DateFirmActionRatingPrice TargetDetails
3/11/2016Dawson JamesReiterated RatingBuyView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for CEL-SCI (NYSEMKT:CVM)
Earnings by Quarter for CEL-SCI (NYSEMKT:CVM)
Earnings History by Quarter for CEL-SCI (NYSEMKT:CVM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q2 2017($0.05)$0.02 millionViewN/AView Earnings Details
2/9/2017Q116$0.01$0.01 millionViewN/AView Earnings Details
8/10/2016Q316($0.03)$0.13 millionViewN/AView Earnings Details
5/10/2016Q2($0.07)$0.03 millionViewN/AView Earnings Details
5/8/2015Q2 2015($0.12)($0.17)$0.10 million$0.20 millionViewN/AView Earnings Details
2/6/2015Q1 2015($0.09)($0.11)$0.07 million$0.14 millionViewN/AView Earnings Details
5/13/2014Q114($0.11)($0.24)$0.02 million$0.07 millionViewN/AView Earnings Details
2/11/2014Q413($0.11)($0.15)$510.39 millionViewN/AView Earnings Details
1/2/2014Q3($0.27)ViewN/AView Earnings Details
5/14/2013Q213($0.01)$0.07 millionViewN/AView Earnings Details
2/8/2013Q1 2013($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for CEL-SCI (NYSEMKT:CVM)
Current Year EPS Consensus Estimate: $-0.4200 EPS
Next Year EPS Consensus Estimate: $-0.2900 EPS


Dividend History for CEL-SCI (NYSEMKT:CVM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for CEL-SCI (NYSEMKT:CVM)
Insider Trades by Quarter for CEL-SCI (NYSEMKT:CVM)
Insider Trades by Quarter for CEL-SCI (NYSEMKT:CVM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/13/2014Geert R KerstenCEOBuy14,999$0.77$11,549.23View SEC Filing  
12/30/2013Geert R KerstenCEOBuy300,000$0.60$180,000.00View SEC Filing  
10/9/2013Geert R KerstenInsiderBuy8,400$0.79$6,636.00View SEC Filing  
6/19/2013Peter R YoungDirectorBuy25,000$0.24$6,000.00View SEC Filing  
6/14/2013Geert R KerstenInsiderBuy145,120$0.24$34,828.80View SEC Filing  
5/20/2013Geert R KerstenCEOBuy40,000$0.25$10,000.00View SEC Filing  
5/2/2013Geert R KerstenCEOBuy118,700$0.27$32,049.00View SEC Filing  
3/27/2013Peter R YoungDirectorBuy25,000$0.23$5,750.00View SEC Filing  
3/26/2013Geert R KerstenCEOBuy348,125$0.21$73,106.25View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for CEL-SCI (NYSEMKT:CVM)
Latest Headlines for CEL-SCI (NYSEMKT:CVM)
finance.yahoo.com logoCEL-SCI Scientist Presents at AAI - IMMUNOLOGY 2017 Meeting
finance.yahoo.com - May 16 at 12:09 PM
finance.yahoo.com logoCEL-SCI Announces Change to the Date of Its Annual Meeting
finance.yahoo.com - May 12 at 5:07 PM
americanbankingnews.com logoCEL-SCI Co. (CVM) Releases Earnings Results
www.americanbankingnews.com - May 11 at 2:46 PM
finance.yahoo.com logoCEL-SCI Corporation Reports Second Quarter Fiscal Year 2017 Financial Results
finance.yahoo.com - May 10 at 4:46 PM
finance.yahoo.com logoA Neurotrope Stock Promotion Scheme is Underway, But Who's Paying For It?
finance.yahoo.com - May 3 at 4:31 PM
americanbankingnews.com logoCEL-SCI (CVM) Given Daily Media Sentiment Rating of 0.03
www.americanbankingnews.com - May 2 at 11:40 PM
finance.yahoo.com logoCEL-SCI Announces $1.51 Million Registered Direct Offering
finance.yahoo.com - May 1 at 4:31 PM
americanbankingnews.com logoCEL-SCI (CVM) Receives Media Impact Rating of 0.29
www.americanbankingnews.com - April 29 at 9:34 PM
finance.yahoo.com logoCEL-SCI Receives Intent to Grant Notice for New Multikine Patent from the European Patent Office
finance.yahoo.com - April 28 at 5:36 PM
finance.yahoo.com logoCEL-SCI Corporation Releases Letter to Shareholders
finance.yahoo.com - April 24 at 9:13 AM
americanbankingnews.com logoCEL-SCI (CVM) Receiving Somewhat Positive Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 20 at 4:54 PM
finance.yahoo.com logoCEL-SCI Scientist Presents at the World Vaccine Congress
finance.yahoo.com - April 12 at 11:41 AM
us.rd.yahoo.com logoCEL-SCI Announces $1.5 Million Registered Direct Offering
us.rd.yahoo.com - March 9 at 5:10 PM
us.rd.yahoo.com logoCEL-SCI Gives Update on Partial Clinical Hold on Phase 3 Head and Neck Cancer Study with Multikine
us.rd.yahoo.com - March 6 at 10:18 AM
streetinsider.com logoCEL-SCI Corp (CVM) Says NYSE Approves Plan to Bring Itself Into Compliance with Listing Standards - StreetInsider.com
www.streetinsider.com - March 1 at 11:18 PM
bizjournals.com logoVienna's Cel-Sci Corp. raises $1 million for head and neck cancer trial - Washington Business Journal
www.bizjournals.com - March 1 at 11:18 PM
biz.yahoo.com logoCEL SCI CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - February 28 at 10:34 AM
finance.yahoo.com logoCEL-SCI Announces That the NYSE MKT Approves Plan
finance.yahoo.com - February 27 at 5:47 PM
us.rd.yahoo.com logoCEL-SCI Scientist Presents New Findings for Rheumatoid Arthritis Treatment Vaccine at Conference
us.rd.yahoo.com - February 21 at 5:55 PM
biz.yahoo.com logoCEL SCI CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities
biz.yahoo.com - February 21 at 5:55 PM
us.rd.yahoo.com logoCEL-SCI Announces $1.0 Million Registered Direct Offering
us.rd.yahoo.com - February 17 at 3:38 PM
us.rd.yahoo.com logo8:31 am CEL-SCI Corp commences approx. $1.0 mln direct offering of common stock; will issue approximately 10 million registered shares of common stock at a purchase price of $0.10 per share
us.rd.yahoo.com - February 17 at 3:38 PM
us.rd.yahoo.com logoCEL-SCI Corporation Reports First Quarter Fiscal 2017 Financial Results
us.rd.yahoo.com - February 10 at 3:06 AM
biz.yahoo.com logoCEL SCI CORP Files SEC form 8-K, Other Events
biz.yahoo.com - December 22 at 9:47 PM
businesswire.com logoCEL-SCI Announces Closing of Public Offering and Receives Audit ... - Business Wire (press release)
www.businesswire.com - December 21 at 10:24 PM


This page was last updated on 5/27/2017 by MarketBeat.com Staff